Lynnet Koh, M.B.A.
Chairman & Founder
Lynnet has successfully led the research, development, manufacturing of Targazyme’s immuno- oncology drugs from idea stage to completion of phase 2 clinical trials where Targazyme’s drug is shown to improve cancer patient survival and quality of life as well as positioning the company for Phase 3 readiness/multiple shots on goal. Key milestones and awards received: FDA Phase 3 Special Protocol Assessment, multiple FDA Orphan Drug DesignaOons, worldwide patents. Major validation received: $40MM+ of prestigious peer-reviewed medical awards for the advancement of the fucosyltransferase recombinant human enzyme technology with leading clinical collaborators, publications in Blood, Clinical Cancer Research and Nature, collaborations with Astellas, Kyowa Hakko Kirin, Vidacord, Poseida TherapeuOcs, Allogene and leading research centers such as MD Anderson Cancer Center and OMRF.
Lynnet has a passion for, and a proven track record with leading transformative technology innovations from the idea stage through design, development, manufacturing, global launch, and achievement of market-leading commercial revenues across multiple industries. They include Targazyme’s novel enzymes with their potential for improving the efficacy, safety, and cost of care for cell therapy, the world’s first generation caller ID product (AT&T Bell Labs) which enables people to see the caller’s name and number, first-generation wireless systems (AT&T Bell Labs) which enables people to be reached anyone, anyplace, anywhere; first-generation voice/video/data infrastructure products (Cisco Systems) which enables people to have voice/ video communications over the internet. Several of the products that she managed commanded #1 market share in their sectors and won best in class awards. Companies, where she held key general management/program leadership roles, include Cisco Systems, AT&T, Qualcomm.
Tom is concurrently the CBO of Taiwan Liposome. Tom was previously the former CEO of Genisphere, VP of Business Development at Baxter, Head of the Business Development Group at Amgen where he directed all M&A and Licensing operaOons and Johnson & Johnson where he was in charge of licensing projects. He was at Donaldson, Lunin & Jenreje New York as Vice President, Biotech Corporate Finance where he led mulOple life sciences debt/equity financings, IPO and acquisiOon advisory projects. Tom received his MBA from the Wharton School of Management, University of Pennsylvannia and Bachelor of Arts Degree from Dartmouth College.
Emmanuelle J. Meuillet is an accomplished scientist, inventor, and entrepreneur focusing on drug discovery and development. Dr. Meuillet obtained a PhD in Biochemistry and Pharmacology from the Louis Pasteur University (France). She completed post-doctoral training at the Children’s Memorial Hospital at Northwestern University in Chicago and at the University of Arizona Comprehensive Cancer Center in Tucson. Over the years, Dr. Meuillet has managed many NIH funded programs bringing in over $9M for research in oncology and experimental therapeutics. She is an experienced manager of national and international multidisciplinary innovative projects. She founded two biotech companies, Phusis Therapeutics, Inc. in 2009 and Theraxen Technologies, LLC in 2016 advancing the development of small molecules. Dr. Meuillet is a consultant for the NIH, DoD, and various foundations and organizations in the US and Europe. She is the author of more than fifty peer-reviewed manuscripts and reviews, she is an inventor on three patents and she belongs to several editorial boards for specialized cancer journals.
Audrey Jakubowski, Ph.D. VP of Regulatory Affairs and QA
Dr. Jakubowski came to Targazyme after a long career in both big and small pharma. She started her career at Bristol Myers, working with dermatological products and then moving to the Bristol Myers Research Center in Wallingford, CT, where she built and led a regulatory group that focused on building a single, international dossier that could be submitted around the globe. During that time, Dr. Jakubowski prepared registration plans and documents for drugs in cancer, cardiovascular, central nervous system, anti-infective and anti-HIV areas for European, Canadian and Japanese submissions. Dr. Jakubowski went on to DuPont, where she was the head of Global Regulatory Affairs for the pharmaceutical division at DuPont where she had responsibility for investigational drugs as well as marketed products, generic drugs, and radiopharmaceuticals. During her 15th year in big pharma, Dr. Jakubowski was responsible for submitting multiple New Drug Applications, both in the U. S. and abroad. She also was the regulatory lead for two FDA advisory committee meetings in the U.S. Dr. Jakubowski was an elected member of the Pharmaceutical Research and Manufacturer’s Association (PhRMA) Regulatory Affairs Committee and was an invited speaker at many professional meetings. Dr. Jakubowski came to California to join Systemix, a cell therapy company, as their Vice President of Regulatory Affairs and Quality Assurance. Dr. Jakubowski went on to SuperGen where she also had responsibility for regulatory affairs and quality assurance and submitted two NDAs for cancer drugs. Dr. Jakubowski went on to support the company’s focus on new molecules that were early on in development, which she continued to do until she retired in 2009. Dr. Jakubowski left retirement to join Targazyme because she feels that the platform technology that Targazyme has developed has the potential to help so many people who are desperate for help with their serious diseases. Dr. Jakubowski received her Ph.D in Physical Chemistry from S.U.N.Y. Buffalo. She also completed a PostDoctoral Fellowship at S.U.N.Y. Buffalo Department of Medicine and another at Rosewell Park Memorial Institute in Buffalo, N.Y.
Richard Martin, Ph.D. VP of CMC and Head of Operations
Dr. Martin is an accomplished pharmaceutical executive with over 20 years of research and development experience in the fields of antibacterial, inflammation, oncology, antiviral, antifungal, cardiovascular and metabolic diseases, sexual dysfunction, as well as glycosciences. An excellent track record of bringing hits to leads, optimizing compounds into development candidates, as well as managing the chemistry, manufacturing, and regulatory activities for both clinical stage and approved drugs. He directed many successful programs of which 4 compounds have entered clinical trials. Collaborated closely with several Big Pharma companies to advance these development compounds following licensing of the assets and participated in joint steering teams. He was instrumental in the CMC efforts that led to the approval of Apricus Biosciences’ first drug Vitaros® in Canada and Europe. Dr. Martin initially served at Tanabe Research Laboratories before joining X-Ceptor therapeutics, which was acquired by Exelixis for their valuable metabolic disease programs. He then held the position of Director of Chemistry at Exelixis before joining RetroVirox as Senior Director of Chemistry, founding partner and investor. Dr. Martin then served as Vice President of Chemistry and Manufacturing at Apricus Biosciences (NexMed USA) where he led the chemistry, manufacturing and supply chain activities at the company. Dr. Martin obtained his Ph.D. from the University of Toronto and pursued postdoctoral studies at The Scripps Research Institute in San Diego with professor Chi-Huey Wong, a pioneer in the field of glycosciences. Dr. Martin has over 30 patent applications, 26 of which have already been granted in the US, over 25 publications in peer-reviewed journals and presentations at various scientific meetings.
Reid Bissonnette, PhD, Lead Scientist, Immuno-Oncology
Dr. Bissonnette is a drug discovery scientist with more than 25 years experience in research and development, from discovery to registration, and with extensive experience in oncology, inflammation, apotive, nuclear receptor biology, hematology and cytokine biology. Specialties include: Oncology, Immunology (immuno-oncology), small molecule, protein/pepOde, biologics, adaptive cell therapies, drug development. Reid previously held senior scientific positions at companies such as Pfizer WRD, Ligand Pharmaceuticals and Huya Pharmaceuticals. Reid received his PhD in Tumor and Cellular Immunology from McGill University.
Rod McEver, MD, Founder/Inventor of Targazyme’s Technologies.
Dr. Rodger McEver also serves as OMRF’s Chief ScienOfic Officer. A cardiovascular biologist and hematologist, he previously headed OMRF’s Cardiovascular Biology Research Program from 2007 to 2016. During his career, he received more than 30 years of continuous funding from the National InsOtutes of Health and served as principal investigator on several major program grants.
McEver’s research focused on how circulating blood cells attach to blood vessels at the sites of Issue injury or infection. His lab discovered the protein P-selection, and his work with this adhesion molecule led to the creation of Adakveo, a drug to treat sickle cell disease that earned FDA approval in 2019.
He has received numerous awards, including a MERIT Award from the National InsOtutes of Health and election as a Fellow of the American Heart Association. He is board-certified in internal medicine and hematology and served as the Alvin Chang Chair in Cardiovascular Biology at OMRF. He also co-founded other biotechnology companies: Selexys PharmaceuOcals Corp., which was acquired by Novartis, and Tetherex PharmaceuOcals.
He received his B.A. degree cum laude from Yale University and his M.D. from the University of Chicago. Aper completing a fellowship at Washington University School of Medicine in St. Louis, he joined the faculty at the University of Texas Health Science Center at San Antonio before establishing his lab at OMRF in 1987.
Lijun Xia, MD, Ph.D., Founder/Inventor of Targazyme’s Technologies
Chair of the Cardiovascular Biology Research Program, Merrick FoundaOon Chair in Biomedical Research. Adjunct Professor in the Department of Biochemistry and Molecular Biology at the University of Oklahoma Health Sciences Center. He received his MD at Binzhou Medical College (China) in 1982 and graduated with his Ph.D. from Soochow University Medical College (China) in 1995. He joined the Oklahoma Medical Research Foundation in 2002. His work has focused on a group of sugars known as O-glycans, yielding important information about liver disease, cancer and other illnesses.
Board of Directors/Key Advisors
Alan Lewis, PhD
Dr. Alan Lewis is the founding Director of Targazyme and was a long Ome board member of Biomarin. Dr. Lewis was the President, CEO, and Chairman of Ambit BioSciences, and previously President and CEO of the Juvenile Diabetes Research FoundaOon and President, CEO, and Director of Novocell, Inc. Prior to Novocell, Dr. Lewis served as CEO and Director of Signal PharmaceuOcals before its acquisition by Celgene, a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for cancer and immunological diseases, aper which he served as President of the Signal Research Division at Celgene. Before joining Signal, Dr. Lewis held the position of Vice President of Research at Wyeth-Ayerst, where he spent 15 years leading research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy, and bone metabolism diseases. Dr. Lewis currently serves as a Director of BioMarin PharmaceuOcal, Inc. He holds a Ph.D. in pharmacology from the University of Wales in Cardiff and completed his postdoctoral training at Yale University.
Mark Frolich, MD
Dr. Frohlich is an experienced medical oncologist and biotechnology executive with expertise in drug development of cell & gene therapies, oncology, and immunology. Dr. Frohlich has been
involved in the development of immunotherapies for cancer for 20 years. He was most recently executive VP of Portfolio Strategy at Juno TherapeuOcs prior to its acquisition by Celgene. He previously served as executive VP of R&D and Chief Medical Officer of Dendreon Corporation, where he led the clinical team responsible for the approval of the first cellular immunotherapy in the US and Europe (Provenge®). Dr. Frohlich is a graduate of Yale College with a BS in Economics and Electrical Engineering summa cum laude, and Harvard Medical School with a Doctor of Medicine degree. He was Chief Medical Resident and completed an internal medicine residency and subsequently completed the oncology fellowship program, both at UCSF.
Gary Frashier, PhD
Mr. Frashier served as Chief ExecuOve Officer and Chairman of OSI PharmaceuOcals, and it was during his tenure at OSI that the leading generic-based cancer drug, “Tarceva” was discovered and developed thru initial human Proof of Concept clinical trials. Tarceva is now sold by Roche and Genentech and has annual sales of over $1.7 billion with continuing expansion into new cancer areas. Astellas Pharma acquired OSI in 2010 for $4 billion. Mr. Frashier has raised over $250 million from a combination of equity financings and other sources has organized many collaborations and joint programs with major pharmaceutical companies and has served as a founder of several life science companies. Prior to OSI, Mr. Frashier served as President, Internacional, and ExecuOve Vice President of Millipore CorporaOon; President and CEO of Waters CorporaOon, the leader in liquid chromatography; and CEO of Genex CorporaOon, a protein engineering company. He has participated as a founder in organizing several biotechnology companies, including Merrimack PharmaceuOcals, Inc.; Eutropics, Inc.; Targazyme and Apex BioVentures AcquisiOon CorporaOon. He currently serves on the Board of Directors of Achillion PharmaceuOcals, Inc. (NASDAQ), ViroXis CorporaOon, Inc., and Metric Medical Devices, Inc., and he is an Advisor to Santalis CorporaOon and StemBioSys. He is a Strategic Partner in SV Life Sciences LP, a major venture capital company. He has served on numerous other private and public life science company Boards, including Maxim PharmaceuOcals, Tekmira PharmaceuOcals (Canada), Apex BioVentures AcquisiOon CorporaOon, Tanox, Inc., Cytoclonal PharmaceuOcals, Exegenics PharmaceuOcals, Aderis Pharmaceuticals, and Alseres Pharmaceuticals. Mr. Frashier has a B.S. in Chemical Engineering from Texas Tech University, which has designated him a “DisOnguished Engineer Graduate,” and an M.B.A. from the Massachusetts Institute of Technology, where he was selected as an “Alfred P. Sloan Fellow.” He is a registered Professional Engineer in Chemical Engineering in Texas.
Art Benvenuto, PhD
Art is the Founding Business Advisory Board member of Targazyme. He is currently the Chairman and Chief executive Officer of Micell Technologies. Prior to being named to his current role, Art served as Chairman, Life Sciences for RA Capital Group, an advisor to venture capital firms, as well as a board member of other biotech and medical device companies. He was also an early principal and the Chairman & CEO of Advanced Tissue Sciences, Inc. (ATS), a public biotechnology firm focused on the field of Issueengineering. Prior to joining ATS, Art served as President and General Manager of Eli Lilly Canada, Inc. and was President & CEO of IVAC Corp., a medical device company previously owned by Eli Lilly (now part of Care Fusion/BD). Art also held various marketing and sales management positions within the pharmaceutical Division of Lilly as well as within the medical device subsidiary, IVAC. He holds a B.S. in Pharmacy and an honorary Doctor of Science from St. John’s University.
Art’s previous board appointments include Scripps Insitute of Medicine and Science; The Scripps Research Insitute; Scripps Memorial Hospital FoundaOon (where he served as President); Project HOPE, international health, and education foundation; La Jolla Cancer FoundaOon (now Sanford-Burnham Medical Research Insitute); Board of Overseers for the University of California, San Diego; Governor’s Council on Biotechnology (California); San Diego Economic Development CorporaOon; City NaOonal Bank (San Diego Advisory Board); and BIOCOM (San Diego), where he was a founding board member. Art has acted as a former board member and advisor to certain other privately-held and publicly-traded biomedical companies.